Brenden Rearick

Brenden Rearick

InvestorPlace Financial News Writer

Expertise: Blockchain, Cryptocurrency, Digital Asset Regulation

Education: BA, Public & Professional Writing and Political Science, University of Pittsburgh

About Brenden:
Brenden Rearick is a Financial News Writer for the Today’s Market team at InvestorPlace, joining the team in 2021. Before joining InvestorPlace, Brenden was a student and a freelance writer, contributing to various periodicals for the University of Pittsburgh and local non-profits.

He primarily covers cryptocurrency and blockchain technology for Today’s Market. His interests span the metaverse, as well as DeFi and Web 3.0 projects.

You can follow Brenden on Twitter.

Recent Articles

Ethereum Price Predictions: Where Will ETH Go After China Bans Crypto Again?

By Brenden Rearick, InvestorPlace Financial News Writer

Ethereum price predictions are becoming a hot item amid China's continued crypto crackdown. Predictions are slightly less bullish now.

Want to Invest in NFL Prospect Kayvon Thibodeaux? Check Out the Rally Crypto.

By Brenden Rearick, InvestorPlace Financial News Writer

The Rally crypto allows creators and influencers a chance to cash in on social status. A college football star is the newest to join Rally.

How Many Times Has China Banned Crypto? 11 Things to Know About the Regulatory Timeline.

By Brenden Rearick, InvestorPlace Financial News Writer

The China crypto crackdown is reaching a boiling point. Regulations today see the government try to completely stomp out its crypto market.

FEDU Stock Rockets 35% as Chinese Education Companies Navigate Regulatory Threats

By Brenden Rearick, InvestorPlace Financial News Writer

FEDU stock is withstanding regulatory blows better than its counterparts. Investors are celebrating the education play's big gains.

NVAX Stock: The Big Covid-19 News Sending Novavax Shooting Higher

By Brenden Rearick, InvestorPlace Financial News Writer

NVAX stock is moving up today on plans to distribute its vaccine abroad. Even after failing to file with the FDA, investors are bullish.

Load More